Is Halozyme Therapeutics (HALO) Pricing Look Interesting After Recent Share Price Volatility

Simply Wall St.03-14

If you are wondering whether Halozyme Therapeutics at around US$63.66 offers good value today, it helps to step back and line up what the current price might be implying about the business. The stock ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619126691?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-14 18:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619126691","market":"nz","top_or_hot":-1,"title":"Is Halozyme Therapeutics (HALO) Pricing Look Interesting After Recent Share Price Volatility","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Halozyme Therapeutics at around US$63.66 offers good value today, it helps to step back and line up what the current price might be implying about the business. The stock ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/is-halozyme-therapeutics-halo-pricing-look-interesting-after\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Halozyme Therapeutics (HALO) Pricing Look Interesting After Recent Share Price Volatility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Halozyme Therapeutics (HALO) Pricing Look Interesting After Recent Share Price Volatility\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-14 18:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/is-halozyme-therapeutics-halo-pricing-look-interesting-after><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Halozyme Therapeutics at around US$63.66 offers good value today, it helps to step back and line up what the current price might be implying about the business. The stock ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/is-halozyme-therapeutics-halo-pricing-look-interesting-after\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/is-halozyme-therapeutics-halo-pricing-look-interesting-after","article_id":"2619126691","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/is-halozyme-therapeutics-halo-pricing-look-interesting-after","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619126691","pubTimestamp":1773483540,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Halozyme Therapeutics at around US$63.66 offers good value today, it helps to step back and line up what the current price might be implying about the business.\nThe stock has been choppy recently, with a 5.5% decline over the last week, a 17.2% decline over the last month, but a 92.4% return over three years and 44.3% over five years, which can leave investors unsure whether the current level reflects opportunity or higher risk.\nRecent coverage has focused on...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HALO":"奥洛兹美医疗","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)"},"translate_title":"最近股价波动后，Halozyme Therapeutics(HALO)的定价看起来有趣吗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"HALO":1.5},"content_text":"If you are wondering whether Halozyme Therapeutics at around US$63.66 offers good value today, it helps to step back and line up what the current price might be implying about the business. The stock has been choppy recently, with a 5.5% decline over the last week, a 17.2% decline over the last month, but a 92.4% return over three years and 44.3% over five years, which can leave investors unsure whether the current level reflects opportunity or higher risk. Recent coverage has focused on Halozyme's position in pharmaceuticals and biotech, along with how the market is reacting to its product portfolio and partnerships. This helps frame these mixed short term moves. For long term holders and new investors alike, this context matters when you are trying to work out whether current pricing is more driven by sentiment or fundamentals. On our valuation checks, Halozyme Therapeutics scores a 3 out of 6. Next we will look at how different methods such as multiples and cash flow models treat the stock, then finish with a broader way to think about valuation that goes beyond a single score.  Find out why Halozyme Therapeutics's 2.2% return over the last year is lagging behind its peers. AdvertisementApproach 1: Halozyme Therapeutics Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model takes estimates of the cash Halozyme Therapeutics might generate in the future and discounts those back to what they could be worth in today’s dollars. It is essentially asking what a stream of future cash flows is worth right now. For Halozyme, the latest twelve month free cash flow is about $637.36 million. Analysts provide cash flow estimates for the next few years, and beyond that Simply Wall St extrapolates the trend to build a longer term view. Under this 2 Stage Free Cash Flow to Equity model, projected free cash flow for 2035 is $1.43b, with interim years such as 2026 and 2027 sitting in the hundreds of millions of dollars. All of these figures are in $ and then discounted back to today. Putting these projections together, the model arrives at an estimated intrinsic value of US$210.11 per share. Versus the current share price of about US$63.66, this implies the stock is 69.7% undervalued based on this DCF framework. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Halozyme Therapeutics is undervalued by 69.7%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks. HALO Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Halozyme Therapeutics. Approach 2: Halozyme Therapeutics Price vs Earnings For a profitable company like Halozyme Therapeutics, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. It links the share price directly to current earnings, which many investors use as a quick sense check on how expensive or cheap a stock might be compared with alternatives. What counts as a “normal” P/E often depends on how quickly earnings are expected to grow and how risky those earnings appear. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty can lead investors to look for a lower P/E. Halozyme currently trades on a P/E of 23.71x. This sits above the Biotechs industry average of 20.88x and above the peer group average of 20.24x. Simply Wall St’s Fair Ratio for Halozyme is 20.10x, which is its proprietary view of what a P/E might look like after considering factors such as earnings growth, profit margins, industry, market cap and risk. Because the Fair Ratio is tailored to the company, it can be more informative than a simple comparison with peers or the industry. With the actual P/E of 23.71x above the Fair Ratio of 20.10x, the shares screen as overvalued on this measure. Result: OVERVALUED NasdaqGS:HALO P/E Ratio as at Mar 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies. Upgrade Your Decision Making: Choose your Halozyme Therapeutics Narrative Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you connect your view of Halozyme Therapeutics’ story to a concrete forecast for revenue, earnings and margins, turn that into your own Fair Value, then compare it with the current price. The platform’s Community page shows how different investors can look at the same facts and reach very different conclusions. For example, some may prefer a cautious Narrative that lines up with a Fair Value around US$59.56 or even the bearish US$51.00 price target. Others may choose a more optimistic Narrative that leans toward a Fair Value around US$84.50 or the bullish US$91.00 price target. All of these will update automatically as new news, guidance or earnings are added. For Halozyme Therapeutics however we will make it really easy for you with previews of two leading Halozyme Therapeutics Narratives: 🐂 Halozyme Therapeutics Bull Case Fair value: US$84.50 Implied discount to fair value: 24.7% below this narrative fair value at the last close of US$63.66 Revenue growth assumption: 15.37% a year  Focuses on Halozyme as a beneficiary of the shift toward subcutaneous drug delivery through its ENHANZE platform and a growing roster of partnered biologics. Builds in analyst assumptions for rising revenue, higher profit margins and buybacks, then discounts those cash flows using a 7.41% required return. Flags risks such as regulatory and reimbursement changes, revenue concentration in a few key partners, patent challenges and rising competition in drug delivery.  🐻 Halozyme Therapeutics Bear Case Fair value: US$59.56 Implied premium to fair value: 6.9% above this narrative fair value at the last close of US$63.66 Revenue growth assumption: 14.66% a year  Centers on the company’s dependence on ENHANZE, with concerns around patent expiries, pricing pressure and shifts in drug delivery technology reducing long term royalty strength. Uses earnings and margin assumptions that still show growth, but applies a lower future P/E multiple and a 7.52% discount rate, which brings the fair value closer to the bearish analyst target of US$51.00. Accepts that royalty streams and new partnerships could remain supportive, while arguing that current expectations may be too optimistic if competition and patent cliffs hit harder than hoped.  If you want to see how other investors are framing these kinds of cases and build your own version, Curious how numbers become stories that shape markets? Explore Community Narratives can be a useful next step. Do you think there's more to the story for Halozyme Therapeutics? Head over to our Community to see what others are saying! NasdaqGS:HALO 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Halozyme Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619126691","isCrawlerRequest":true}